CN111303053A - Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application - Google Patents

Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application Download PDF

Info

Publication number
CN111303053A
CN111303053A CN202010179508.8A CN202010179508A CN111303053A CN 111303053 A CN111303053 A CN 111303053A CN 202010179508 A CN202010179508 A CN 202010179508A CN 111303053 A CN111303053 A CN 111303053A
Authority
CN
China
Prior art keywords
cyclopenta
dihydro
pyrimidin
fluoro
difluorophenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010179508.8A
Other languages
Chinese (zh)
Other versions
CN111303053B (en
Inventor
徐涛
卢玲
陈栋
秦玉婷
赵维峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocean University of China
Original Assignee
Ocean University of China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean University of China filed Critical Ocean University of China
Priority to CN202010179508.8A priority Critical patent/CN111303053B/en
Publication of CN111303053A publication Critical patent/CN111303053A/en
Application granted granted Critical
Publication of CN111303053B publication Critical patent/CN111303053B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a cyclopenta [ d ] group]Pyrimidine compounds, pharmaceutically acceptable salts, solvates or prodrugs thereof and applications thereof, wherein the compounds have the following structural formula:

Description

Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a novel cyclopenta [ d ] pyrimidine compound with antitumor activity, and pharmaceutically acceptable salt, solvate or prodrug thereof and application thereof.
Background
Renal cancer is a malignant tumor originating in the epithelial system of the urinary tubule of the renal parenchyma, and is known as renal cell carcinoma in academic terms, which is also called renal adenocarcinoma, and is referred to as renal cancer for short. The kidney cancer accounts for about 2-3% of adult malignant tumor and 80-90% of adult malignant tumor. The rising rate of renal cancer has ranked first among malignant tumors in recent years. Clinical treatment shows that kidney cancer is insensitive to radiotherapy and chemotherapy, and targeted antitumor drugs represented by VEGFR inhibitors sorafenib and sunitinib are first-line treatment drugs of late-stage kidney cancer. Although there are up to ten FDA-approved drugs for the treatment of renal cancer, these drugs have a very limited therapeutic effect on metastatic renal cancer and are susceptible to drug resistance. Therefore, finding and confirming a new target for the action of a specific drug for treating kidney cancer is a very urgent and significant task.
Hypoxia inducible factor 2a (HIF-2a) is a transcription factor that affects the expression of a variety of genes. It is responsible for regulating and controlling the reaction of cells to the anoxic environment and promoting the survival and proliferation of cells in the anoxic environment. HIF-2a regulated genes affect a variety of physiological processes including metabolism, angiogenesis, cell proliferation, tumor metastasis, inflammation, and escape from anti-cancer immune responses. It is thought to be associated with the exacerbation of a variety of cancers, and plays a very important role, especially in Clear Cell Renal Cell carcinoma (ccRCC). Therefore, the development of HIF-2a target inhibition drugs is of great significance.
There are currently few reports of HIF-2a inhibitors, with only one inhibitor PT2385 being in phase 1 clinical stage. Therefore, the development of new improved or more potent HIF-2a inhibitors is of great clinical significance for inhibiting the occurrence, metastasis and recurrence of tumors.
Disclosure of Invention
The invention aims to provide a cyclopenta [ d ] pyrimidine compound and a pharmaceutically acceptable salt, solvate or prodrug thereof and application thereof, and the cyclopenta [ d ] pyrimidine compound can be used as an HIF-2a inhibitor and can be used for treating or/and preventing HIF-2 α -related diseases or symptoms of mammals (including human beings).
In order to achieve the purpose, the technical scheme of the invention is as follows:
cyclopenta [ d ] pyrimidines and pharmaceutically acceptable salts, solvates or prodrugs thereof, which have the structure shown in formula (I):
Figure BDA0002411984510000021
wherein: r1Selected from aryl or heteroaryl;
R2selected from hydrogen or alkyl;
R3、R4selected from hydrogen, halogen or alkyl;
x is selected from oxygen, nitrogen and sulfur atoms.
In the above scheme, R is1Is phenyl, biphenyl, monocyclic heteroaryl, bicyclic heteroaryl or pyridyl.
In a further embodiment, the phenyl or pyridyl is substituted with at least one substituent selected from the group consisting of halogen, cyano, C1-C4 alkyl, and C1-C4 alkoxy.
As described aboveIn the scheme, the R2Is hydrogen or methyl.
In the above scheme, R is3、R4Is hydrogen, fluorine or methyl.
Preferably, the compound is selected from the following compounds:
3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
2-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (3,4- (methylenedioxy) phenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3, 5-dichlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3, 5-dimethoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-chlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-methoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-trifluoromethylphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- ((5-fluoropyridin-3-yl) oxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4-fluoro-3- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (2, 4-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3, 4-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (2, 3-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) amino) benzonitrile;
4- (3, 5-difluoroanilino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (2, 3-difluorophenylsulfanyl) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-bromophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
3-fluoro-5- (((5R) -7-hydroxy-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
(5R) -4- (3, 5-difluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
3-fluoro-5- ((7-hydroxy-6, 6-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (3, 5-difluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(R) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
(S) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
(R) -4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(S) -4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(S) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile;
(R) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile;
(S) -4- (3, 5-difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(R) -4- (3, 5-difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol.
A pharmaceutical composition comprising a compound of any of the above and pharmaceutically acceptable salts, solvates or prodrugs thereof, and optionally one or more pharmaceutically acceptable excipients or carriers.
The application of the compound and the pharmaceutically acceptable salt, solvate or prodrug thereof in preparing medicines for treating and/or preventing diseases or symptoms related to hypoxia inducible factor 2 α in mammals.
In a further embodiment, the disease or condition associated with hypoxia inducible factor 2 α is selected from the group consisting of cancer, inflammation, metabolic disease;
the cancer comprises skin cancer, lung cancer, urinary system tumor, blood tumor, breast cancer, glioma, digestive system tumor, reproductive system tumor, lymphoma, menstrual system tumor, brain tumor, and head and neck cancer; the inflammation comprises pneumonia, enteritis, nephritis, arthritis and trauma infection; the metabolic diseases comprise obesity, dyslipidemia and hyperlipidemia.
Through the technical scheme, the cyclopenta [ d ] pyrimidine compound and the pharmaceutically acceptable salt, solvate or prodrug thereof can effectively inhibit HIF-2a and HIF-1 β from forming a dimer compound, have strong in-vitro binding capacity with HIF-2 α protein, and can effectively inhibit expression of HIF-2a downstream target gene VEGF.
The cyclopenta [ d ] pyrimidine compound shown in the formula (I) comprises isomers, racemes, enantiomers, diastereomers, enantiomer enrichments, deuterions, solvates and esters thereof; the compound of the formula I and the isomer, racemate, enantiomer, diastereomer, enantiomer enrichment, deuteron, solvate and ester thereof can also form solvate, such as hydrate, alcoholate and the like. The compounds may also be prodrugs or forms which release the active ingredient upon metabolic change in vivo. The selection and preparation of appropriate prodrug compounds is well within the skill of those in the art. Generally for the purposes of the present invention, the solvate forms of pharmaceutically acceptable solvents such as water, ethanol, etc. are equivalent to the non-solvate forms.
The compounds of formula (I) of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. The term "pharmaceutically acceptable salt" refers to salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. The salts may be prepared by reacting a compound of the invention with a suitable organic or inorganic acid.
The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium capable of delivering an effective amount of an active agent of the present invention, without interfering with the biological activity of the active agent, and without toxic side effects to the host or patient, and representative carriers include water, oils, vegetables and minerals, cream bases, lotion bases, ointment bases, and the like. These include suspending agents, viscosity enhancers, skin penetration enhancers, and the like. Their preparation is known to those skilled in the cosmetic or topical pharmaceutical field. For additional information on the vector, reference may be made to Remington, the science and practice of pharmacy,21stBd., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.
The term "excipient" generally refers to a carrier, diluent, and/or vehicle necessary to formulate an effective pharmaceutical composition.
Drawings
FIG. 1 shows the results of an HIF-2 α transcriptional activity inhibition assay;
FIG. 2 is a diagram showing the inhibition of angiogenesis in zebra fish;
FIG. 3 is a statistical (. mu.m) graph of the length of the blood vessels between the zebra fish internodes.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below.
It will be clear to those skilled in the art that the materials used and the methods of operation are well known in the art, unless otherwise specified, in the following text. Unless otherwise stated, wherein:
(1) temperatures are expressed in degrees Celsius (. degree. C.) and the operation is carried out at room temperature, which is generally 15-35℃, preferably 20-30℃, more preferably 20-25℃;
(2) drying the organic solvent with anhydrous sodium sulfate, removing the solvent by vacuum evaporation with a rotary evaporator, and keeping the bath temperature not higher than 60 deg.C;
(3) the reaction process was followed by Thin Layer Chromatography (TLC);
(4) the final product has satisfactory hydrogen nuclear magnetic resonance spectrum (1H-NMR)、And Mass Spectrometry (MS) data.
Example 1:
3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 1)
Figure BDA0002411984510000051
(1) 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (intermediate 1-a):
Figure BDA0002411984510000052
1,5,6, 7-Tetrahydrocyclopenta [ d ] pyrimidin-4-one (6.8g, 50.0mmol) was added to phosphorus oxychloride (60mL), warmed to 110 ℃ and stirred for 10 h. TLC showed the reaction was complete, cooled to room temperature, the solvent was evaporated under reduced pressure, the residue was poured into water, the pH was adjusted to 7 with saturated sodium bicarbonate solution, ethyl acetate was added and extracted 2 times, the organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to dryness to give 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (7.5g, 98%) which was reacted directly in the next step. LCMS (ESI) M/z 155.1[ M +1 ].
(2) 1-oxo-4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (intermediate 1-B):
Figure BDA0002411984510000053
to a solution of 4-chloro-6, 7-dihydro-5H-cyclopentapyrimidine (5.0g, 32.5mmol) in chloroform (80mL) at 0 deg.C was added 77% m-chloroperoxybenzoic acid (10.1g, 58.5mmol) in portions. Stir at room temperature overnight. TLC showed the reaction was complete, cooled to 0 deg.C and NaHCO was added3(25g, 196mmol) in water (100mL) and Na added2CO3(14g, 128mmol) in water (100mL), stirred for 0.5H, separated, the aqueous phase extracted with chloroform (100mL), the organic phases combined, dried over anhydrous sodium sulfate, and concentrated to dryness to give 1-oxo-4-chloro-6, 7-dihydro-5H-cyclopenta [ d [ -d ] ] -chloro]Pyrimidine (5.5g, 100%) was reacted in the next step without purification.
(3) 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 1-C):
Figure BDA0002411984510000061
reacting 1-oxo-4-chloro-6, 7-dihydro-5H-cyclopenta [ d]Pyrimidine (5.0g, 29.3mmol) was added to acetic anhydride (40mL, 425 mmol). Heating to 110 ℃, stirring for 5H, TLC (thin layer chromatography) for reaction completion, cooling to room temperature, evaporating the solvent under reduced pressure, pouring the residue into water, adjusting the pH to 7 with saturated sodium bicarbonate solution, adding dichloromethane for extraction for 2 times, washing the organic phase with saline, drying with anhydrous sodium sulfate, concentrating to dryness, and purifying the obtained crude product by column chromatography (petroleum ether/ethyl acetate ═ 6:1) to obtain 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ═ 1]]Pyrimidin-7-ylethyl ester (2.7g, 43.3%). 1H NMR (400MHz, CDCl)3)δ8.91(s,1H),6.16(m,1H),3.10-3.16(m,1H),2.91–2.99(m,1H),2.66–2.75(m,1H),2.14(s,3H),2.06–2.12(m,1H).LCMS(ESI):m/z:213.1[M+1]。
(4)4- (3-cyano-5-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ D ] pyrimidin-7-ylethyl ester (intermediate 1-D):
Figure BDA0002411984510000062
4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (0.50g, 2.4mmol), 3-fluoro-5-hydroxybenzonitrile (0.39g, 2.8mmol), potassium carbonate (0.50g, 3.6mmol) were added to DMF (15 mL). The temperature was raised to 85 ℃ and stirred overnight. TLC showed the reaction was complete, cooled to room temperature, poured into water, extracted 2 times with ethyl acetate, the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate and concentrated to dryness, and purified by column chromatography (petroleum ether/ethyl acetate ═ 5:1) to give 4- (3-cyano-5-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (0.50g, 68%). 1HNMR (400MHz, CDCl 3). delta.8.69 (s,1H),7.34(s,1H),7.29(dd,1H),7.26(dd,1H),6.16(M,1H),3.11-3.19(M,1H), 2.94-2.99 (M,1H), 2.70-2.79 (M,1H), 2.11-2.17 (M,4H). LCMS (ESI): M/z:314.1[ M +1 ].
(5) 3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (compound 1):
4- (3-cyano-5-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (0.20g, 0.64mmol), lithium hydroxide monohydrate (67mg, 1.6mmol) was added to a solution of tetrahydrofuran/water (2:1,10 mL). Stir at room temperature overnight. TLC showed the reaction was complete, added 1M HCl solution to adjust pH to 5-6, extracted 2 times with ethyl acetate, the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate and concentrated to dryness, and purified by column chromatography (petroleum ether/ethyl acetate ═ 2:1) to give 3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (0.12g, 71%). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.34(s,1H),7.29(dd,1H),7.23(dd,1H),5.26(M,1H),3.09-3.16(M,1H), 2.87-2.93 (M,1H), 2.63-2.67 (M,1H), 2.11-2.15 (M,1H). LCMS (ESI): M/z:272.1[ M +1 ].
Example 2:
4- (3, 5-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 2)
Figure BDA0002411984510000071
(1)4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester:
Figure BDA0002411984510000072
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3, 5-difluorophenol in 78.1% yield. 1H NMR (400MHz, CDCl 3). delta.8.69 (s,1H),7.34(s,1H),7.29(dd,1H),7.26(dd,1H),6.16(M,1H),3.11-3.19(M,1H), 2.94-2.99 (M,1H), 2.70-2.79 (M,1H), 2.11-2.17 (M,4H). LCMS (ESI): M/z:307.1[ M +1 ].
(2)4- (3, 5-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 2):
prepared from 4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 82.5% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),6.71-6.76(M,3H),5.27(M,1H),4.78(s,1H),3.08-3.15(M,1H), 2.83-2.89 (M,1H), 2.57-2.66 (M,1H), 2.04-2.16 (M,1H). LCMS (ESI): M/z:265.1[ M +1 ].
Example 3
2-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 3)
Figure BDA0002411984510000081
(1)4- (3-cyano-4-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 3-a):
Figure BDA0002411984510000082
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 2-fluoro-5-hydroxybenzonitrile in 76.5% yield. LCMS (ESI) M/z 314.1[ M +1 ].
(2) 2-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (compound 3):
prepared from 4- (3-cyano-4-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 81.5% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.62 (s,1H),7.46(M,1H),7.40(M,1H),7.29(M,1H),5.25(M,1H),3.36(s,1H),3.09-3.17(M,1H), 2.87-2.92 (M,1H), 2.60-2.69 (M,1H), 2.09-2.14 (M,1H). LCMS (ESI): M/z:272.1[ M +1 ].
Example 4
4- (3,4- (methylenedioxy) phenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 4)
Figure BDA0002411984510000083
(1)4- (3,4- (methylenedioxy) phenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 4-a):
Figure BDA0002411984510000084
prepared from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester, sesamol in 71.2% yield using a method similar to that of example 1 (4). LCMS (ESI) M/z 315.1[ M +1 ].
(2)4- (3,4- (methylenedioxy) phenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 4):
prepared from 4- (3,4- (methylenedioxy) phenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 86.7% yield using a method similar to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.65 (s,1H),6.82(d,1H),6.65(s,1H),6.59(d,1H),6.01(s,1H),5.25(M,1H),4.86(s,1H),3.07-3.14(M,1H), 2.82-2.90 (M,1H), 2.59-2.65 (M,1H), 2.07-2.13 (M,1H), LCMS ESI, (M/z: 273.1[ M +1 ].
Example 5:
4- (3, 5-Dichlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 5)
Figure BDA0002411984510000091
(1)4- (3, 5-Dichlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (intermediate 5-a):
Figure BDA0002411984510000092
prepared from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester and 3, 5-dichlorophenol in a similar manner to example 1(4) and in 71.8% yield. LCMS (ESI) M/z 340.1[ M +1 ].
(2)4- (3, 5-Dichlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 5):
prepared from 4- (3, 5-dichlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 86.7% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.27(dd,1H),7.12(d,2H),5.26(M,1H),4.64(s,1H),3.07-3.14(M,1H), 2.82-2.91 (M,1H), 2.58-2.67 (M,1H), 2.07-2.14 (M,1H), LCMS (ESI): M/z:298.1[ M +1 ].
Example 6:
4- (3, 5-Dimethoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 6)
Figure BDA0002411984510000101
(1)4- (3, 5-dimethoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 6-a):
Figure BDA0002411984510000102
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3, 5-dimethoxyphenol in 79.8% yield. LCMS (ESI) M/z 331.1[ M +1 ].
(2)4- (3, 5-Dimethoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 6):
prepared from 4- (3, 5-dimethoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester in a yield of 81.9% by a similar method to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),6.37(s,1H),6.30(s,2H),5.27(M,1H),4.78(s,1H),3.78(d,6H),3.07-3.14(M,1H), 2.84-2.90 (M,1H), 2.60-2.65 (M,1H), 2.07-2.12 (M,1H). LCMS (ESI): M/z:289.1[ M +1 ].
Example 7:
4- (3-fluoro-5-chlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 7)
Figure BDA0002411984510000103
(1)4- (3-fluoro-5-chlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 7-a):
Figure BDA0002411984510000104
prepared from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester and 3-fluoro-5-chlorophenol in a yield of 73.6% by a method similar to that of example 1 (4). LCMS (ESI) M/z 324.1[ M +1 ].
(2)4- (3-fluoro-5-chlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 7):
prepared from 4- (3-fluoro-5-chlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 82.5% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.01(M,2H),6.86(M,1H),5.27(M,1H),4.86(s,1H),3.07-3.15(M,1H), 2.83-2.91 (M,1H), 2.59-2.67 (M,1H), 2.07-2.16 (M,1H). LCMS (ESI): M/z:281.3[ M +1 ].
Example 8:
4- (3-fluoro-5-methoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 8)
Figure BDA0002411984510000111
(1)4- (3-fluoro-5-methoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 8-a):
Figure BDA0002411984510000112
prepared from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester and 3-fluoro-5-methoxyphenol in a 75.8% yield by a method similar to that of example 1 (4). LCMS (ESI) M/z 319.1[ M +1 ].
(2)4- (3-fluoro-5-methoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 8):
prepared from 4- (3-fluoro-5-methoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester in 82.5% yield using a method similar to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),6.50-6.55(M,3H),5.26(M,1H),4.92(s,1H),3.79(s,3H),3.07-3.14(M,1H), 2.82-2.90 (M,1H), 2.57-2.64 (M,1H), 2.06-2.16 (M,1H). LCMS (ESI): M/z:277.1[ M +1 ].
Example 9:
4- (3-fluoro-5-trifluoromethylphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 9)
Figure BDA0002411984510000121
(1)4- (3-fluoro-5-trifluoromethylphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 9-a):
Figure BDA0002411984510000122
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3-fluoro-5-trifluoromethylphenol in 76.9% yield. LCMS (ESI) M/z 357.1[ M +1 ].
(2)4- (3-fluoro-5-trifluoromethylphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 9):
prepared from 4- (3-fluoro-5-trifluoromethylphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester in a yield of 82.5% by a similar method to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.65 (s,1H),7.27(M,1H),7.24(M,1H),7.15(dt,1H),5.27(M,1H),4.83(s,1H),3.10-3.17(M,1H), 2.85-2.93 (M,1H), 2.60-2.69 (M,1H), 2.08-2.18 (M,1H). LCMS (ESI): M/z:315.1[ M +1 ].
Example 10:
4- ((5-Fluoropyridin-3-yl) oxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 10)
Figure BDA0002411984510000123
(1)4- ((5-fluoropyridin-3-yl) oxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (intermediate 10-a):
Figure BDA0002411984510000124
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3-fluoro-5-hydroxypyridine in 81.5% yield. LCMS (ESI) M/z 290.1[ M +1 ].
(2)4- ((5-fluoropyridin-3-yl) oxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 10):
prepared from 4- ((5-fluoropyridin-3-yl) oxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in a 76.4% yield using a method similar to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.34(s,1H),7.29(dd,1H),7.25(dd,1H),5.26(M,1H),5.68(s,1H),3.09-3.16(M,1H), 2.87-2.93 (M,1H), 2.63-2.67 (M,1H), 2.11-2.15 (M,1H). LCMS ESI (M/z: 248.1[ M +1 ].
Example 11
4-fluoro-3- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 11)
Figure BDA0002411984510000131
(1)4- (3-cyano-2-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 11-a):
Figure BDA0002411984510000132
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 4-fluoro-3-hydroxybenzonitrile in 78.5% yield. LCMS (ESI) M/z 314.1[ M +1 ].
(2) 4-fluoro-3- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (compound 11):
prepared from 4- (3-cyano-2-fluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 81.5% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.60 (s,1H),7.57-7.63(M,2H),7.29-7.34(M,1H),7.25(dd,1H),5.26(M,1H),4.42(s,1H),3.13-3.20(M,1H), 2.84-2.97 (M,1H), 2.61-2.69 (M,1H), 2.09-2.18 (M,1H), LCMS ESI, (M/z: 272.1[ M +1 ].
Example 12:
4- (2, 4-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 12)
Figure BDA0002411984510000141
(1)4- (2, 4-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (intermediate 12-A):
Figure BDA0002411984510000142
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 2, 4-difluorophenol in 71.1% yield. LCMS (ESI) M/z 307.1[ M +1 ].
(2)4- (2, 4-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 12):
prepared from 4- (2, 4-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 82.5% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.61 (s,1H),7.16-7.21(M,1H),6.90-6.99(M,2H),7.25(dd,1H),5.27(M,1H),4.95(s,1H),3.12-3.19(M,1H), 2.87-2.95 (M,1H), 2.59-2.67 (M,1H), 2.08-2.17 (M,1H), LCMS ESI: (M/z: 265.1[ M +1 ].
Example 13:
4- (3, 4-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 13)
Figure BDA0002411984510000143
(1)4- (3, 4-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (intermediate 13-A):
Figure BDA0002411984510000144
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3, 4-difluorophenol in 71.6% yield. LCMS (ESI) M/z 307.1[ M +1 ].
(2)4- (3, 4-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 13):
prepared from 4- (3, 4-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 82.8% yield by a similar method to that used in example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.63 (s,1H),7.20(M,1H),7.01-7.06(M,1H),6.88-6.93(M,1H),5.26(M,1H),4.09(s,1H),3.08-3.15(M,1H), 2.83-2.91 (M,1H), 2.58-2.67 (M,1H), 2.03-2.13 (M,1H), LCMS (ESI): M/z:265.1[ M +1 ].
Example 14:
4- (2, 3-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 14)
Figure BDA0002411984510000151
(1)4- (2, 3-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (intermediate 14-A):
Figure BDA0002411984510000152
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 2, 3-difluorophenol in 75.7% yield. LCMS (ESI) M/z 307.1[ M +1 ].
(2)4- (2, 3-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 14):
prepared from 4- (2, 3-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 80.2% yield by a similar method to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.63 (s,1H),7.20(M,1H),7.04(M,1H),6.90(M,1H),5.26(M,1H),4.61(s,1H),3.08-3.16(M,1H), 2.83-2.92 (M,1H), 2.59-2.67 (M,1H), 2.07-2.16 (M,1H). LCMS (ESI): M/z:265.1[ M +1 ].
Example 15:
3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) amino) benzonitrile (Compound 15)
Figure BDA0002411984510000161
(1)4- (3-cyano-5-fluorophenylamino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 15-a):
Figure BDA0002411984510000162
4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (0.50g, 2.4mmol), 3-fluoro-5-cyanoaniline (0.35g, 2.6mmol) were added to isopropanol (15mL), 2 drops of concentrated HCl were added, and the mixture was heated to 85 ℃ and refluxed overnight. TLC showed the reaction was complete, cooled to rt, evaporated to dryness and purified by column chromatography (petroleum ether/ethyl acetate 2:1) to give 4- (3-cyano-5-fluorophenylamino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (0.56g, 76%). 1H NMR (400MHz, CDCl 3). delta.8.69 (s,1H),7.34(s,1H),7.29(dd,1H),7.26(dd,1H),6.16(M,1H),3.11-3.19(M,1H), 2.94-2.99 (M,1H), 2.70-2.79 (M,1H), 2.11-2.17 (M,4H). LCMS (ESI): M/z:313.1[ M +1 ].
(2) 3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) amino) benzonitrile (compound 15):
4- (3-cyano-5-fluorophenylamino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (0.20g, 0.64mmol), lithium hydroxide monohydrate (67mg, 1.6mmol) were added to a tetrahydrofuran/water (2:1,10mL) solution. Stir at room temperature overnight. TLC showed the reaction was complete, added 1M HCl solution to adjust pH to 5-6, extracted 2 times with ethyl acetate, the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate and concentrated to dryness, and purified by column chromatography (petroleum ether/ethyl acetate 1:1) to give 3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) amino) benzonitrile (0.12g, 71%). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.34(s,1H),7.29(dd,1H),7.25(dd,1H),5.26(M,1H),5.68(s,1H),3.09-3.16(M,1H), 2.87-2.93 (M,1H), 2.63-2.67 (M,1H), 2.11-2.15 (M,1H). LCMS ESI (M/z: 271.1[ M +1 ].
Example 16:
4- (3, 5-Difluoroanilino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 16)
Figure BDA0002411984510000171
(1)4- (3, 5-difluoroanilino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 16-A):
Figure BDA0002411984510000172
prepared in a similar manner to example 15(1) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3, 5-difluoroaniline, in 65.7% yield. LCMS (ESI) M/z 306.1[ M +1 ].
(2)4- (3, 5-difluoroaniline) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 16):
prepared from 4- (3, 5-difluoroanilino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester in a yield of 80.5% by a similar method to that of example 15 (2). 1H NMR (400MHz, CDCl 3). delta.8.57 (s,1H),7.50(dd,2H),6.56(dd,1H),5.00(M,1H),4.56(s,1H),2.93-3.00(M,1H), 2.70-2.78 (M,1H), 2.47-2.53 (M,1H), 1.92-1.99 (M,1H). LCMS (ESI): M/z:264.1[ M +1 ].
Example 17:
4- (2, 3-Difluorophenylthio) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 17)
Figure BDA0002411984510000173
(1)4- (2, 3-difluorophenylthio) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 17-a):
Figure BDA0002411984510000174
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 2, 3-difluorothiophenol in 71.8% yield. LCMS (ESI) M/z 323.1[ M +1 ].
(2)4- (2, 3-difluorophenylsulfanyl) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 17):
prepared from 4- (2, 3-difluorophenylthio) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester in 77.2% yield by a similar method to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.75 (s,1H),7.12(dd,2H),6.89(dd,1H),5.20(M,1H),4.46(s,1H),2.92-2.99(M,1H), 2.69-2.77 (M,1H), 2.55-2.63 (M,1H), 2.05-2.09 (M,1H). LCMS (ESI): M/z:281.1[ M +1 ].
Example 18:
4- (3-fluoro-5-bromophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 18)
Figure BDA0002411984510000181
(1)4- (3-fluoro-5-bromophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 18-a):
Figure BDA0002411984510000182
prepared in a similar manner to example 1(4) from 4-chloro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3-fluoro-5-bromophenol in 73.6% yield. LCMS (ESI) M/z 368.1[ M +1 ].
(2)4- (3-fluoro-5-bromophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 18):
prepared from 4- (3-fluoro-5-bromophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester in 82.5% yield using a method similar to that of example 1 (5). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.18(M,2H),6.89(dd,1H),5.27(M,1H),4.86(s,1H),3.07-3.15(M,1H), 2.80-2.89 (M,1H), 2.59-2.67 (M,1H), 2.04-2.16 (M,1H), LCMS (ESI): M/z:326.1[ M +1 ].
Example 19:
3-fluoro-5- (((5R) -7-hydroxy-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 19)
Figure BDA0002411984510000191
(1) (2R) -2-methyl-5- (prop-2-ylidene) cyclopentanecarboxylic acid ethyl ester (intermediate 19-A):
Figure BDA0002411984510000192
to a 500mL round bottom flask was added (R) - (+) -pulegone (7.61g,50mmol), anhydrous NaHCO3(1.25g,15mmol) and anhydrous ether (50 mL). The reaction mixture was cooled with an ice bath under nitrogen. Liquid bromine (2.6mL,50mmol) was added dropwise. The mixture was filtered and carefully added to NaOEt (21%, 42mL,110mmol) in an ice bath. The mixture was stirred at room temperature overnight, then 100mL of 5% HC1 and 30mL of diethyl ether were added. The aqueous phase was extracted with diethyl ether (2 × 30mL), the combined organic phases were washed with water, dried and concentrated. Semicarbazide hydrochloride (3.75g,34mmol), NaOAc (37.5g,46mmol), ethanol (40mL) and water (40mL) were added and the mixture was heated under reflux for 3 hours and then stirred at room temperature overnight. The mixture was treated with 100mL of water and 30mL of diethyl ether. The aqueous phase was extracted with diethyl ether (2 × 30 mL). The combined organic phases were washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by distillation under the reduced pressure (at 0.8mm Hg73-76 ℃ C.) to give ethyl (2R) -2-methyl-5- (propan-2-ylidene) cyclopentanecarboxylate (6.5g, 66%). 1H NMR (400MHz, CDCl)3)δ3.58–3.28(m,2H),2.87–2.77(m,1H),2.59–2.45(m,1H),2.41–2.22(m,3H),2.13(d,J＝5.1Hz,6H),1.78–1.72(m,1H),1.45(d,J＝7.0Hz,3H),1.36(d,J＝7.1Hz,3H).LCMS(ESI):m/z:197.1[M+1]。
(2) (2R) -2-methyl-5-oxocyclopentanecarboxylic acid ethyl ester (intermediate 19-B):
Figure BDA0002411984510000193
ethyl (2R) -2-methyl-5- (prop-2-ylidene) cyclopentacarboxylate (5.0g,25.5mmol) was added to ethyl acetate (100mL), cooled to-68 ℃ and ozonated oxygen was passed over for 5 hours. TLC check, reaction complete, reaction mixture at room temperature with nitrogen purge until color disappeared. Ethyl acetate was removed under reduced pressure and the residue was dissolved in 30mL of acetic acid and cooled with ice water, and zinc powder (10g) was added. The solution was stirred for 30 minutes and then filtered. The filtrate was neutralized with 2N NaOH (250ml) and saturated NaHC03 solution, and the aqueous phase was extracted with diethyl ether (3X50 mL). The organic phases are combined, washed with water, anddried over sodium sulfate and concentrated to give ethyl (2R) -2-methyl-5-oxocyclopentacarboxylate (3.8g, 88%). 1H NMR (400MHz, CDCl)3)δ4.24–4.12(m,2H),2.72(d,J＝11.3Hz,1H),2.62–2.50(m,1H),2.42–2.24(m,2H),2.21–2.10(m,1H),1.39–1.50(m,1H),1.25(td,J＝7.1,1.3Hz,3H),1.17–1.12(m,3H).LCMS(ESI):m/z:171.1[M+1]。
(3) (R) -2-mercapto-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-ol (intermediate 19-C):
Figure BDA0002411984510000201
ethyl (2R) -2-methyl-5-oxocyclopentecarboxylate (3.0g, 17.6mmol), thiourea (1.5g,19.7mmol), KOH (1.3g, 23.2mmol) was added to ethanol (60 mL). The mixture was heated to reflux for 10 hours. Cool and remove the solvent under reduced pressure, and the residue is adjusted to pH 1 with 3N HCl at 0 ℃ and then extracted with DCM (3 × 50 mL). The solvent was removed and purified by column chromatography (petroleum ether/ethyl acetate ═ 2:1) to give (R) -2-mercapto-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-ol (1.9g, 59%). LCMS (ESI) M/z 183.1[ M +1 ].
(4) (R) -5-methyl-6, 7-dihydro-5H-cyclopenta [ D ] pyrimidin-4-ol (intermediate 19-D):
Figure BDA0002411984510000202
in the presence of (R) -2-mercapto-5-methyl-6, 7-dihydro-5H-cyclopenta [ d]Raney nickel (3.0g) and aqueous ammonia (5ml) were added to a suspension of pyrimidin-4-ol (1.6g, 8.8mmol) and water (20 ml). The mixture was heated to reflux for 10 h. Filtering while hot, concentrating the filtrate to obtain (R) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d]Pyrimidin-4-ol (1.3g, 99%). 1H NMR (400MHz, CDCl)3)δ8.06(s,1H),3.30(s,1H),3.04–2.73(m,2H),2.29(dd,J＝14.1,7.6Hz,1H),1.75–1.55(m,1H),1.28(s,3H).LCMS(ESI):m/z:151.1[M+1]。
(5) (R) -4-chloro-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (intermediate 19-E):
Figure BDA0002411984510000203
prepared from (R) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-ol in 80.5% yield using a method similar to that of example 1 (1). LCMS (ESI) M/z 169.5[ M +1 ].
(6) (R) -1-oxo-4-chloro-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (intermediate 19-F):
Figure BDA0002411984510000211
prepared from (R) -4-chloro-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine by a method similar to that of example 1 (2).
(7) (5R) -4-chloro-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 19-G):
Figure BDA0002411984510000212
prepared from (R) -1-oxo-4-chloro-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine in a yield of 61.6% by a similar method to example 1 (3). 1H NMR (400MHz, Chloroform-d) Δ 8.90(s,1H), 6.31-5.99 (M,1H), 3.58-3.28 (M,1H), 2.87-2.76 (M,1H), 2.47-2.18 (M,2H),2.12(s,3H), 1.48-1.33 (M,3H). LCMS (ESI). M/z:227.5[ M +1 ].
(8) (5R) -4- (3-cyano-5-fluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 19-H):
Figure BDA0002411984510000213
prepared from (5R) -4-chloro-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3-fluoro-5-hydroxybenzonitrile in a yield of 81.2% by a similar method to that of example 1 (4). LCMS (ESI) M/z 328.1[ M +1 ].
(9) 3-fluoro-5- (((5R) -7-hydroxy-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (compound 19):
by a method similar to that of example 1(5), from (5R) -4- (3-cyanoYl-5-fluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d]Pyrimidin-7-ylethyl ester preparation in 80.7% yield. 1H NMR (400MHz, CDCl)3)δ8.65(s,1H),7.33(s,1H),7.28(d,J＝7.7Hz,1H),7.22(d,J＝9.3Hz,1H),5.39–5.12(m,1H),3.33–2.77(m,1H),2.38–2.17(m,2H),1.52–1.36(m,3H).LCMS(ESI):m/z:286.1[M+1]。
Example 20:
(5R) -4- (3, 5-Difluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 20)
Figure BDA0002411984510000221
(1) (5R) -4- (2, 3-Difluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 20-A):
Figure BDA0002411984510000222
prepared in a similar manner to example 1(4) from (5R) -4-chloro-5 methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3, 5-difluorophenol in 77.8% yield. LCMS (ESI) M/z 321.1[ M +1 ].
(2) (5R) -4- (3, 5-Difluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 20):
by a method similar to that of example 1(5), starting from (5R) -4- (2, 3-difluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ]]Pyrimidin-7-ylethyl ester preparation in 76.2% yield. 1H NMR (400MHz, CDCl)3)δ8.66(s,1H),6.75(m,3H),5.37–5.11(m,1H),3.35–2.79(m,1H),2.40–2.16(m,2H),1.51–1.34(m,3H).LCMS(ESI):m/z:279.1[M+1]。
Example 21:
3-fluoro-5- ((7-hydroxy-6, 6-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 21)
Figure BDA0002411984510000223
(1)3, 3-dimethyl adipate dimethyl ester (intermediate 21-a):
Figure BDA0002411984510000224
to a solution of 4, 4-dimethylcyclohexanone (5.0g, 40mmol) in glacial acetic acid (100ml) was added a solution of CrO3(12.0g, 120mmol) in glacial acetic acid (50ml) and water (50 ml). The mixture was stirred at 60 ℃ overnight. Cooled to room temperature and adjusted to pH 14 with 40% aq NaOH. The mixture was washed with diethyl ether (2 × 200ml) and the aqueous phase was adjusted to pH 1 with concentrated hydrochloric acid. The solution was extracted with ether (3 × 200ml), the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was dissolved in methanol (100ml), thionyl chloride (4ml) was added and the solution was warmed to 60 ℃ and stirred for 6 hours, cooled to room temperature and concentrated under reduced pressure to give the crude product which was purified by column chromatography (petroleum ether/ethyl acetate 10:1) to give dimethyl 3, 3-dimethyladipate as a colourless oil (7.1g, 88.6% yield).
(2)4, 4-dimethyl-2-oxo-cyclopentanecarboxylic acid methyl ester (intermediate 21-B):
Figure BDA0002411984510000231
dimethyl 3, 3-dimethyladipate (6.0g, 29.7mmol) was added to methanol (200ml) and toluene (20ml), sodium metal (1.4g, 60mmol) was added, the mixture was heated under reflux overnight, cooled, concentrated and the residue was purified by column chromatography (petroleum ether/ethyl acetate 10:1) to give methyl 4, 4-dimethyl-2-oxo-cyclopentanecarboxylate (4.3g, 85.6% yield) as a colorless oil. LCMS (ESI) M/z 171.1[ M +1 ].
(3) 2-mercapto-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-ol (intermediate 21-C):
Figure BDA0002411984510000232
prepared in a similar manner to example 19(3) from methyl 4, 4-dimethyl-2-oxo-cyclopentanecarboxylate in 58.9% yield. LCMS (ESI) M/z 197.1[ M +1 ].
(4)5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ D ] pyrimidin-4-ol (intermediate 21-D):
Figure BDA0002411984510000233
prepared from 2-mercapto-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-ol in a 96.5% yield by a similar procedure to example 19 (3). LCMS (ESI) M/z 165.1[ M +1 ].
(5) 4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (intermediate 21-E):
Figure BDA0002411984510000234
prepared from 5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-ol in 81.6% yield using a method similar to that of example 1 (1). LCMS (ESI) M/z 183.5[ M +1 ].
(6) 1-oxo-4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine (intermediate 21-F):
Figure BDA0002411984510000241
prepared from 4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidine in a similar manner to example 1 (2).
(7) 4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 21-G):
Figure BDA0002411984510000242
by a method similar to that of example 1(3), starting from 1-oxo-4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ]]Pyrimidine was prepared in 53.4% yield. 1H NMR (400MHz, CDCl)3)δ8.84(s,1H),5.91(s,1H),2.89–2.72(m,2H),1.24(s,3H),1.04(s,3H).LCMS(ESI):m/z:241.5[M+1]。
(8)4- (3-cyano-5-fluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester (intermediate 21-H):
Figure BDA0002411984510000243
prepared in a similar manner to example 1(4) from 4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3-fluoro-5-hydroxybenzonitrile in 77.6% yield. LCMS (ESI) M/z 342.1[ M +1 ].
(9) 3-fluoro-5- ((7-hydroxy-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (compound 21):
by a method similar to example 1(5), from 4- (3-cyano-5-fluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ]]Pyrimidin-7-ylethyl ester was prepared in 87.5% yield. 1H NMR (400MHz, CDCl)3)δ8.63(s,1H),7.33(s,1H),7.28(s,1H),7.21(s,1H),4.74(s,1H),2.84(d,J＝16.2Hz,1H),2.71(d,J＝16.3Hz,1H),1.32(s,3H),1.11(s,3H).LCMS(ESI):m/z:300.1[M+1]。
Example 22:
4- (3, 5-Difluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 22)
Figure BDA0002411984510000251
(1)4- (2, 3-Difluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-yl ethyl ester (intermediate 22-a):
Figure BDA0002411984510000252
prepared in a similar manner to example 1(4) from 4-chloro-5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-7-ylethyl ester, 3, 5-difluorophenol in 76.9% yield. LCMS (ESI) M/z 335.1[ M +1 ].
(2)4- (3, 5-Difluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 22):
by a method similar to that of example 1(5), starting from 4- (2, 3-difluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ]]Pyrimidin-7-ylethyl ester preparation in 80.8% yield. 1H NMR (400MHz, CDCl)3)δ8.64(s,1H),6.75-6.70(m,3H),4.73(s,1H),2.82(d,J＝16.2Hz,1H),2.68(d,J＝16.2Hz,1H),1.31(s,3H),1.10(s,3H).LCMS(ESI):m/z:293.1[M+1]。
Example 23:
(R) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 23)
Figure BDA0002411984510000253
(1) 3-fluoro-5- ((7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (intermediate 23-a):
Figure BDA0002411984510000261
Dess-Martin oxidant (156mg, 0.40mmol) was added to a solution of the 3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (100mg, 0.40mmol) in dichloromethane (50mL) at room temperature. Stir for 1h and TLC showed the reaction was complete. The reaction mixture was concentrated and the residue was partitioned between ethyl acetate and dilute aqueous sodium thiosulfate and saturated aqueous sodium bicarbonate. The ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated to dryness to give 3-fluoro-5- ((7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (81mg, yield 81%). LCMS (ESI) M/z 270.1[ M +1 ].
(2) (R) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 23):
RuCl (p-isopropyltoluene) [ (S, S) -Ts-DPEN ] (2mg, 0.003mmol) was added to a nitrogen flushed solution of 3-fluoro-5- ((7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (10mg, 0.03mmol), formic acid (7mg, 0.15mmol) and triethylamine (0.015mL, 0.10mmol) in dichloromethane (5mL) at 0 ℃. The reaction vial was sealed and placed in a 4 ℃ freezer overnight. TLC showed the reaction was complete and the residue was purified by column chromatography (dichloromethane: methanol ═ 20:1) to give (R) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (5mg, 50%). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),7.35(s,1H),7.29(dd,1H),7.23(dd,1H),5.26(M,1H),3.08-3.16(M,1H), 2.88-2.93 (M,1H), 2.64-2.68 (M,1H), 2.11-2.15 (M,1H). LCMS (ESI): M/z:272.1[ M +1 ].
Example 24:
(S) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (Compound 24)
Figure BDA0002411984510000262
RuCl (p-isopropyltoluene) [ (R, R) -Ts-DPEN ] (2mg, 0.003mmol) was added to a nitrogen flushed solution of 3-fluoro-5- ((7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (10mg, 0.03mmol), formic acid (7mg, 0.15mmol) and triethylamine (0.015mL, 0.10mmol) in dichloromethane (5mL) at 0 ℃. The reaction vial was sealed and placed in a 4 ℃ freezer overnight. TLC showed the reaction was complete and the residue was purified by column chromatography (dichloromethane: methanol ═ 20:1) to give (S) -3- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (6mg, 60%). 1H NMR (400MHz, CDCl 3). delta.8.67 (s,1H),7.35(s,1H),7.29(dd,1H),7.23(dd,1H),5.26(M,1H),3.09-3.16(M,1H), 2.88-2.93 (M,1H), 2.63-2.68 (M,1H), 2.10-2.15 (M,1H). LCMS (ESI): M/z:272.1[ M +1 ].
Example 25:
(R) -4- (3, 5-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 25)
Figure BDA0002411984510000271
(1)4- (3, 5-Difluorophenoxy) -5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one (intermediate 25-A):
Figure BDA0002411984510000272
prepared from 4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol in 68.8% yield using a method similar to that of example 23 (1). LCMS (ESI) M/z 263.1[ M +1 ].
(2) (R) -4- (3, 5-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 25):
prepared from 4- (3, 5-difluorophenoxy) -6, 6-difluoro-5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one in 78% yield by a method similar to that in example 23 (2). 1H NMR (400MHz, CDCl 3). delta.8.66 (s,1H),6.70-6.76(M,3H),5.27(M,1H),4.78(s,1H),3.08-3.14(M,1H), 2.82-2.89 (M,1H), 2.57-2.66 (M,1H), 2.04-2.16 (M,1H). LCMS (ESI): M/z:265.1[ M +1 ].
Example 26:
(S) -4- (3, 5-Difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 26)
Figure BDA0002411984510000281
Prepared from 4- (3, 5-difluorophenoxy) -6, 6-difluoro-5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one in 81% yield using a similar procedure to that of example 24. 1H NMR (400MHz, CDCl 3). delta.8.65 (s,1H),6.70-6.76(M,3H),5.27(M,1H),4.78(s,1H),3.08-3.14(M,1H), 2.82-2.88 (M,1H), 2.58-2.66 (M,1H), 2.04-2.16 (M,1H). LCMS (ESI): M/z:265.1[ M +1 ].
Example 27:
(S) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (compound 27)
Figure BDA0002411984510000282
(1)3- ((6, 6-difluoro-7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (intermediate 27-a):
Figure BDA0002411984510000283
the 3-fluoro-5- ((7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile (80mg, 0.30mmol), 3-methoxypropylamine (160mg, 1.80mmol), pivalic acid (6mg, 0.06mmol) were placed in a mixed solution of toluene (20mL) and cyclohexane (10mL) and heated at reflux with a Dean-Stark trap attached for 10H. Cooled to room temperature, the reaction mixture was evaporated to dryness and the residue was dissolved in acetonitrile (10 mL). 1-chloromethyl-4-fluoro-1, 4-diammonium bicyclo [2.2.2] octane bis (tetrafluoroborate) (682mg, 0.85mmol) and anhydrous sodium sulfate (86mg, 0.60mmol) were added. Heating to 70 ℃, and continuing stirring for reaction for 2 h. TLC showed the reaction was complete, cooled to room temperature, and the reaction mixture was treated with 1M HCl (3mL, 3.0mmol) and stirred at room temperature for 1 h. The reaction mixture was evaporated and the residue partitioned between ethyl acetate and water. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to dryness, and the crude product was purified by column chromatography (dichloromethane: methanol ═ 30:1) to give 3- ((6, 6-difluoro-7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (20mg, yield 23%). LCMS (ESI) M/z 306.1[ M +1 ].
(2) (S) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (compound 27):
RuCl (p-isopropyltoluene) [ (R, R) -Ts-DPEN ] (2mg, 0.003mmol) was added to a nitrogen flushed solution of 3- ((6, 6-difluoro-7 oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (10mg, 0.03mmol), formic acid (7mg, 0.15mmol) and triethylamine (0.015mL, 0.10mmol) in dichloromethane (5mL) at 0 ℃. The reaction vial was sealed and placed in a 4 ℃ freezer overnight. TLC showed the reaction was complete and the residue was purified by column chromatography (dichloromethane: methanol ═ 20:1) to give (S) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (6mg, 60%). 1H NMR (400MHz, CDCl 3). delta.8.69 (s,1H),7.36(s,1H),7.31(dd,1H),7.25(dd,1H),5.50(M,1H),3.29-3.46(M,2H),. LCMS (ESI): M/z:308.1[ M +1 ].
Example 28:
(R) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (compound 28)
Figure BDA0002411984510000291
RuCl (p-isopropyltoluene) [ (S, S) -Ts-DPEN ] (2mg, 0.003mmol) was added to a nitrogen flushed solution of 3- ((6, 6-difluoro-7-oxo-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (10mg, 0.03mmol), formic acid (7mg, 0.15mmol) and triethylamine (0.015mL, 0.10mmol) in dichloromethane (5mL) at 0 ℃. The reaction vial was sealed and placed in a 4 ℃ freezer overnight. TLC showed the reaction was complete and the residue was purified by column chromatography (dichloromethane: methanol ═ 20:1) to give (R) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile (5mg, 50%). 1H NMR (400MHz, CDCl 3). delta.8.69 (s,1H),7.37(s,1H),7.31(dd,1H),7.24(dd,1H),5.51(M,1H),3.28-3.44(M,2H),. LCMS (ESI): M/z:308.1[ M +1 ].
Example 29:
(S) -4- (3, 5-Difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 29)
Figure BDA0002411984510000301
(1)4- (3, 5-Difluorophenoxy) -6, 6-difluoro-5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one (intermediate 29-a):
Figure BDA0002411984510000302
prepared from 4- (3, 5-difluorophenoxy) -5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one in 25% yield using a method similar to that of example 27 (1). LCMS (ESI) M/z 299.1[ M +1 ].
(2) (S) -4- (3, 5-Difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (Compound 29):
prepared from 4- (3, 5-difluorophenoxy) -6, 6-difluoro-5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one in 61% yield by a method similar to that in example 27 (2). 1H NMR (400MHz, CDCl 3). delta.8.69 (s,1H),6.73-6.79(M,3H),5.52(M,1H),3.38-3.51(M,2H). LCMS (ESI). M/z:301.1[ M +1 ].
Example 30:
(R) -4- (3, 5-Difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol (compound 30)
Figure BDA0002411984510000303
Prepared from 4- (3, 5-difluorophenoxy) -6, 6-difluoro-5, 6-dihydro-7H-cyclopenta [ d ] pyrimidin-7-one in a 65% yield using a similar procedure to that of example 28. 1H NMR (400MHz, CDCl 3). delta.8.68 (s,1H),6.72-6.79(M,3H),5.51(M,1H),3.36-3.48(M,2H). LCMS (ESI). M/z:301.1[ M +1 ].
Biological experiments
1.VEGF ELISA measurement
786-0 cells in logarithmic growth phase were seeded in 96-well plates (Fisher Scientific) at 7500 cells per well (180. mu.L/well), and after 4h of culture, 20. mu.L of different concentrations of compound stock was added to each well to give final concentrations as follows (μ M): 0.01, 0.05, 0.25, 1.25, 6.25, 30. After about 20h, the medium was removed by aspiration and 180 μ L of growth medium was provided to each well. Add 20 μ L of a fresh stock of 6 test compound to each well. Hypoxic (1% oxygen + 5% carbon dioxide + 94% nitrogen) culture for 24h, the cell culture medium was removed. Then, in a manner conforming to the manufacturer's recommendations, the following R is adopted&VEGF concentrations were determined by ELISA kits purchased from D Systems. The reaction was stopped by adding 50. mu.L of Celltiter Glo reagent to each well, and the plate was gently shaken to sufficiently progress the stop reaction. The cell-seeded plates were subjected to CellTiter-Glo luminescent cell viability assay (Promega) and the light absorbance of each well was immediately measured at a wavelength of 450nm using a microplate reader. EC was calculated by analyzing data using a dose-response-inhibition (four parameter) equation by GraphPadPrism50The results are shown in Table 1.
EC for selected Compounds in the determination of Table 1, VEGF ELISA50
Figure BDA0002411984510000311
Figure BDA0002411984510000321
Note: positive control drug: PT-2385.
As shown in the experimental results in Table 1: compounds 1, 2, 5, 8, 10, 12, 23, 25, 26 all had significant activity in inhibiting VEGF expression, with compounds 2, 23, and 25 having better activity than the positive control PT-2385.
2. Testing compound interactions with HIF-2 α protein using the SPRi System
1) Principle of experiment
The biomolecule interaction system is a Surface Plasma Resonance Imaging (SPRi) system based on microarray technology, thousands of sampling points on a chip are shot by adopting two-dimensional CCD technology, the interaction among various biomolecules is analyzed in real time, and no mark is needed. Therefore, the specificity of molecular combination is known, the kinetic data of molecular combination is accurately calculated, and the combination process of biological molecules is known. The method is widely used for the determination of various biological systems, including the interaction among various small molecular compounds, polypeptides, proteins, oligonucleotides and saccharides. Kinetic data such as binding curves, binding, dissociation, equilibrium dissociation constants, etc. can be obtained by data Analysis and fitting with PLEXERA SPR Date Analysis Module (DAM) Analysis software.
2) Experimental methods
The compound was placed on the surface of the biochip Graft-to-PCL by means of the SpotBot3 microarray control software in Arrayit, SpotBot3 needle spot platform, and the compound was crosslinked on the surface of the biochip by ultraviolet light for 15 min. Diluting the initial concentration of protein at 0.1-1 μ M with PBS buffer solution according to a certain proportion, and injecting prepared compounds with different concentrations for detection. The data obtained were analyzed and fitted according to the PLEXERA SPR Date Analysis Module (DAM) Analysis software to obtain binding kinetics constants, the results of which are shown in Table 2.
Buffer (buffer): 1 XPBS
A regeneration liquid: Gly-Hcl (PH 2)
The sample introduction flow rate is 1 mul/s, and the sample introduction time is 180 s; the dissociation flow rate is 1 mul/s, and the sample introduction time is 200 s;
the regeneration flow rate is 2 mul/s, and the regeneration time is 200 s.
3) Results of the experiment
The binding constant (ka), dissociation constant (KD), and equilibrium dissociation constant (KD) for example compounds to HIF-2 α protein are shown in table 2.
TABLE 2 binding kinetics constants of Compounds to HIF-2 α protein
Figure BDA0002411984510000322
Figure BDA0002411984510000331
As can be seen from the results of the experiments in Table 2, it was determined that the test compounds bound to HIF-2 α protein, wherein Compounds 1 and 2 had stronger binding ability to HIF-2 α than the positive control PT 2385.
3. Luciferase reporter gene assay (Luciferase assay) for detecting inhibition of HIF-2 α transcriptional activity by compounds
HEK293T17 cells were plated in a 24 well plate, cultured to 50% -60% confluence, 100. mu.l DMEM was placed in a 1.5ml EP tube, a suitable volume of pcs2-HIF2 α -myc plasmid, pcs2-flag plasmid (control), HRE-miniP-luciferase plasmid (reflecting HIF- α transcriptional activity), Renilla luciferase reporter plasmid (internal reference) was added, a volume (μ l) of Polyetherimide (PEI) 2-4 times the plasmid mass (μ g) was added, mixing and centrifugation were performed, the mixture was placed in a 37 ℃ incubator and left to stand for 15 minutes, at the end of the standing, cells were removed, medium was aspirated and washed twice with a suitable amount of D-hanks, the previous plasmid was supplemented to the desired volume, transfected, added to a 24 well plate, cultured for 6 hours at 37 ℃, cells were removed, medium containing 20% FBS was added, compounds 3, 6,7, 9, 20 μ M was added to the final concentration, cells were transfected, cells were added to a 24 μ M, cells were cultured for 6 hours, cells were added to a 24 well plate, cells were added to a standard, cells culture medium was added to a 96 well plate, cells was added to a dry lysis solution, cells was added to a 1.1-shake a lysis solution, a 1-96 well lysis solution, a test was performed using a dry lysis solution, a dry lysis solution was performed, a test was performed, a dry lysis solution was added to a dry lysis.
As can be seen from fig. 1, overexpression of HIF-2 α resulted in a significant increase in fluorescence values, and a significant decrease in fluorescence values was observed after treatment with compounds 3, 6, and 7, demonstrating that compounds 3, 6, and 7 were able to inhibit the transcriptional activity of HIF-2 α (. P <0.05,. P <0.01,. P < 0.0001).
4. Zebra fish in vivo experiment for detecting whether compound can inhibit angiogenesis activity
Sexually mature and healthy transgenic Tg (flk1:: eGFP) heterozygous fish and WT (wild type) fish are mated and embryos are collected and placed in a fresh PTU-containing embryo culture solution to be incubated at a constant temperature of 28.5 ℃; setting a proper concentration gradient, adding the compound mother solution into an embryo culture solution, diluting a low-concentration solution by a high-concentration solution to obtain the low-concentration solution, and selecting sorafenib with the working concentration of 5mmol/L as a positive control. When the embryos developed to 4hpf, healthy embryos of the same development period were selected, placed in 24-well plates, 10 per well, and the residual embryo culture solution was carefully blotted with a disposable pipette. The plate was incubated with 500. mu.l of an embryo culture solution containing compound (10. mu.M) in an embryo incubator for 48 h. The embryos are placed in a 96-well plate, individuals with vascular fluorescence are selected, the membrane is peeled off, an appropriate amount of tricaine solution is used for anesthesia, the embryos are placed in 2% (w/v) methylcellulose gel for arrangement, 52hpf (hpf, hours post-fertilization) is observed under an inverted fluorescence microscope, and pictures are taken. Internode vessel length (μm) was measured for each fish using imagePro Plus6, statistics were summarized. The angiogenesis and blood vessel length statistics of the transgenic zebra fish are shown in fig. 2 and fig. 3.
As shown in figures 2 and 3, significant incomplete development of blood vessels can be observed after the compound 6 and the compound 7 are added for 48 hours, and internode blood vessel length statistics are carried out on different groups of zebra fish, and the results show that the internode blood vessel length of the zebra fish treated by the compound 6 and the compound 7 is obviously reduced, and the function of inhibiting angiogenesis is probably exerted by inhibiting the activity of HIF-2 α.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims (9)

1. A cyclopenta [ d ] pyrimidine compound and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein the compound has a structure represented by formula (i):
Figure FDA0002411984500000011
wherein: r1Selected from aryl or heteroaryl;
R2selected from hydrogen or alkyl;
R3、R4selected from hydrogen, halogen or alkyl;
x is selected from oxygen, nitrogen and sulfur atoms.
2. Cyclopenta [ d ] according to claim 1]A pyrimidine compound and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is1Is phenyl, biphenyl, monocyclic heteroaryl, bicyclic heteroaryl or pyridyl.
3. A cyclopenta [ d ] pyrimidine compound, or a pharmaceutically acceptable salt, solvate or prodrug thereof, according to claim 2, wherein the phenyl or pyridyl group is substituted with at least one substituent selected from the group consisting of halogen, cyano, C1-C4 alkyl, and C1-C4 alkoxy.
4. Cyclopenta [ d ] according to claim 1]A pyrimidine compound and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is2Is hydrogen or methyl.
5. Cyclopenta [ d ] according to claim 1]A pyrimidine compound and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is3、R4Is hydrogen, fluorine or methyl.
6. The cyclopenta [ d ] pyrimidine compound according to any one of claims 1 to 5, wherein the compound is selected from the group consisting of:
3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
2-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (3,4- (methylenedioxy) phenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3, 5-dichlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3, 5-dimethoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-chlorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-methoxyphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-trifluoromethylphenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- ((5-fluoropyridin-3-yl) oxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4-fluoro-3- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (2, 4-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3, 4-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (2, 3-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) amino) benzonitrile;
4- (3, 5-difluoroanilino) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (2, 3-difluorophenylsulfanyl) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
4- (3-fluoro-5-bromophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
3-fluoro-5- (((5R) -7-hydroxy-5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
(5R) -4- (3, 5-difluorophenoxy) -5-methyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
3-fluoro-5- ((7-hydroxy-6, 6-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
4- (3, 5-difluorophenoxy) -5, 5-dimethyl-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(R) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
(S) -3-fluoro-5- ((7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) benzonitrile;
(R) -4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(S) -4- (3, 5-difluorophenoxy) -6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(S) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile;
(R) -3- ((6, 6-difluoro-7-hydroxy-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) oxy) -5-fluorobenzonitrile;
(S) -4- (3, 5-difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol;
(R) -4- (3, 5-difluorophenoxy) -6, 6-difluoro-6, 7-dihydro-5H-cyclopenta [ d ] pyrimidin-4-yl) -7-ol.
7. A pharmaceutical composition comprising a compound of any one of claims 1-5 and a pharmaceutically acceptable salt, solvate or prodrug thereof, and optionally one or more pharmaceutically acceptable excipients.
8. Use of a compound of any one of claims 1-5, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, in the manufacture of a medicament for the treatment and/or prevention of a disease or condition associated with hypoxia inducible factor 2 α in a mammal.
9. The use according to claim 9, wherein the disease or condition associated with hypoxia inducible factor 2 α is selected from the group consisting of cancer, inflammation, metabolic disease;
the cancer comprises skin cancer, lung cancer, urinary system tumor, blood tumor, breast cancer, glioma, digestive system tumor, reproductive system tumor, lymphoma, menstrual system tumor, brain tumor, and head and neck cancer; the inflammation comprises pneumonia, enteritis, nephritis, arthritis and trauma infection; the metabolic diseases comprise obesity, dyslipidemia and hyperlipidemia.
CN202010179508.8A 2020-03-16 2020-03-16 Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application Active CN111303053B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010179508.8A CN111303053B (en) 2020-03-16 2020-03-16 Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010179508.8A CN111303053B (en) 2020-03-16 2020-03-16 Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application

Publications (2)

Publication Number Publication Date
CN111303053A true CN111303053A (en) 2020-06-19
CN111303053B CN111303053B (en) 2023-01-17

Family

ID=71152328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010179508.8A Active CN111303053B (en) 2020-03-16 2020-03-16 Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application

Country Status (1)

Country Link
CN (1) CN111303053B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407712B2 (en) 2020-03-19 2022-08-09 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749704A (en) * 1985-03-07 1988-06-07 Sankyo Company Limited Cyclopenta[d]pyrimidine derivatives and use as antidepressants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749704A (en) * 1985-03-07 1988-06-07 Sankyo Company Limited Cyclopenta[d]pyrimidine derivatives and use as antidepressants

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407712B2 (en) 2020-03-19 2022-08-09 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
US11787762B2 (en) 2020-03-19 2023-10-17 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

Also Published As

Publication number Publication date
CN111303053B (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US11672799B2 (en) 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions
US9623029B2 (en) 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
KR20160132491A (en) Biaryl kinase inhibitors
CN115175679A (en) Methods of treating estrogen receptor-related disorders
KR20220052918A (en) Peptide conjugates of cytotoxins as therapeutic agents
CN102858754A (en) RAF inhibitor compounds and methods of use thereof
WO2019052557A1 (en) μ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE
WO2018126898A1 (en) Thienopyrimidine derivative, preparation method therefor, and application thereof in manufacturing of antitumor drugs
US7652135B2 (en) Compositions useful as inhibitors of protein kinases
WO2023142518A1 (en) Hydroxynaphthalenone-phenylboronic acid compound, preparation method, and use
CN109867675B (en) Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof
US11944616B2 (en) Dizocilpine derivatives as peripheral NMDA receptor antagonists
CN111303053B (en) Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application
CN109776607B (en) Aryl phosphorus oxygen and aryl phosphorus sulfur compounds, and preparation method and application thereof
EP1911451A1 (en) Protein-kinase CK2 inhibitors and their therapeutic applications
WO2023125928A1 (en) Menin inhibitor and use thereof
CN103087060B (en) High activity paichongding isomer and preparation method thereof
CA3230542A1 (en) Novel ras inhibitors
CN114621135A (en) LPA1 small molecule antagonist
Das et al. Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors
CN115475253B (en) Lapatinib-cancer cell stem inhibitor conjugate, preparation method, pharmaceutical composition and application
CN111484504B (en) Optical isomer of ACC inhibitor and application thereof
CN114907354B (en) Sulfonamide polycyclic compound and preparation method and application thereof
CN114269747B (en) 1&#39;,2&#39; -dihydro-3&#39;H-spiro [ cyclobutane 1,4&#39; -isoquinoline ] -3&#39; -one derivative and application thereof
CN110483547B (en) Simple phenol conjugate of dihydroartemisinin, synthetic method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant